MedCity News
FEBRUARY 11, 2024
HHS recently published guidance outlining voluntary cybersecurity performance goals for the healthcare sector. Taylor Lehmann, a cybersecurity executive at Google Cloud, noted that “what is on HHS paper will most likely become what is in the actual final rulemaking or new regulatory requirements that become law.
pharmaphorum
FEBRUARY 11, 2024
MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
FEBRUARY 11, 2024
As we forge ahead in the behavioral health field, finding the right balance between technological solutions and whole-person care will be essential. Workforce challenges, changes to the way reimbursements work, new medication monitoring options and a laser focus on the personalized solutions that specialty pharmacies can provide are all trends to watch.
PharmaTech
FEBRUARY 11, 2024
Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
FEBRUARY 11, 2024
Bright Health Group recently announced that it is adopting NeueHealth as its corporate brand name after it shed its insurance business and is focusing on its value-based consumer care business. But getting rid of the Bright Health name doesn’t get rid of its financial problems, experts say.
MedCity News
FEBRUARY 11, 2024
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
Expert insights. Personalized for you.
116 
Let's personalize your content